Akero Therapeutics (NASDAQ:AKRO) Receives New Coverage from Analysts at Roth Capital

Roth Capital began coverage on shares of Akero Therapeutics (NASDAQ:AKRO) in a report released on Monday, BenzingaRatingsTable reports. The firm issued a buy rating and a $34.00 target price on the stock.

Separately, JPMorgan Chase & Co. reissued a sell rating and set a $18.00 target price on shares of ABB in a research note on Monday.

Shares of Akero Therapeutics stock opened at $20.64 on Monday. Akero Therapeutics has a one year low of $16.06 and a one year high of $21.94.

In other Akero Therapeutics news, Director Seth Loring Harrison bought 900,000 shares of the business’s stock in a transaction on Monday, June 24th. The stock was bought at an average price of $16.00 per share, with a total value of $14,400,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Global Strategic Fund I. Venbio bought 250,000 shares of the business’s stock in a transaction on Monday, June 24th. The shares were acquired at an average cost of $16.00 per share, with a total value of $4,000,000.00. The disclosure for this purchase can be found here.

About Akero Therapeutics

Akero Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development and commercialization of transformative treatments for serious metabolic diseases with high unmet medical need. Its lead product candidate is AKR-001, which completed Phase Ib clinical trial for the treatment of non-alcoholic steatohepatitis disease.

Featured Story: What is a Real Estate Investment Trust (REIT)?

Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.